Form 4 for BBOT BridgeBio Oncology Therapeutics, Inc.
Accepted 2026-07-06 16:34:53 ET · period of report 2026-07-01 · accession 0001213900-26-075538 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2026-07-06 16:34 | 2026-07-01 | BBOT | Chen Bihua | Dir, 10% | J - Other | $0.00 | 0 | 6.08M | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | J | D | 4,528,186 | $0.00 | 0 | I Via Helix Holdings II LLC | — | — | (F1) Represents a pro rata distribution to the members of Helix Holdings II LLC (the "Sponsor") for no consideration. (F5) Sponsor is the record holder of the securities reported herein. Fund III, Fund V, and Master Fund are the members of Sponsor. Bihua Chen is the manager of Sponsor and has voting and investment discretion with respect to the shares held of record by Sponsor. Each of Fund III, Fund V, Master Fund and Ms. Chen disclaims any beneficial ownership of the securities held by Sponsor other than to the extent of any pecuniary interest she or it may have therein, directly or indirectly. |
| 2 | Common | Common Stock | 2026-07-01 | J | A | 2,692,459 | $0.00 | 4,879,995 | I Via Fund III | — | — | (F2) Cormorant Private Healthcare Fund III, LP ("Fund III"), which is an investment vehicle managed by Cormorant Asset Management, LP ("CAM"), is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration. (F6) CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. |
| 3 | Common | Common Stock | 2026-07-01 | J | A | 1,704,862 | $0.00 | 5,010,332 | I Via Fund V | — | — | (F3) Cormorant Private Healthcare Fund V, LP ("Fund V"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration. (F6) CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. |
| 4 | Common | Common Stock | 2026-07-01 | J | A | 130,865 | $0.00 | 6,083,221 | I Via Master Fund | — | — | (F4) Cormorant Global Healthcare Master Fund, LP ("Master Fund"), which is an investment vehicle managed by CAM, is a member of the Sponsor and received such shares in a pro rata distribution by the Sponsor for no consideration. (F6) CAM serves as the investment manager to Fund III, Cormorant Private Healthcare Fund IV, LP ("Fund IV"), Fund V, and Master Fund (collectively, the "Cormorant Funds"). Cormorant Private Healthcare GP III, LLC ("GP III") is the general partner of Fund III; Cormorant Private Healthcare GP IV, LLC ("GP IV") is the general partner of Fund IV; Cormorant Private Healthcare GP V, LLC ("GP V") is the general partner of Fund V; and Cormorant Global Healthcare GP, LLC ("Global GP") is the general partner of the Master Fund. Bihua Chen serves as the managing member of GP III, GP IV, GP V, and Global GP, and as the general partner of CAM. Accordingly, Ms. Chen has voting and investment discretion with respect to the shares held by each of the Cormorant Funds and CAM. Ms. Chen disclaims any beneficial ownership of the securities held by each of the Cormorant Funds other than to the extent of any pecuniary interest she may have therein, directly or indirectly. |